Why 4DMedical and Spacetalk Are Raising Capital—and What It Means for Investors

Source: Kapitales Research

Highlights:

• 4DMedical secures CE Mark for CT:VQ™ and raises $83 million
• Spacetalk Limited launched a AU$6.0 million placement to fund app enhancements and working capital needs.
• Both companies are enhancing their portfolios, with 4DMedical expanding into the EU market and Spacetalk aiming for technological growth in the consumer sector.

4DMedical Expands with CE Mark and AU$83 Million Placement
4DMedical (ASX: 4DX) has received CE Mark certification for its CT:VQ™, a CT-based ventilation-perfusion imaging solution. The certification enables the company to begin commercial operations across the European Union, significantly expanding its market potential. 4DMedical Limited was trading at AU$6.445, reflecting a ~3% increase. Investors have responded positively to the CE Mark news, indicating optimism about the company’s potential for growth in the European market.
Along with the CE Mark, 4DMedical completed an AU$83 million private placement at an issue price of AU$5.90 per share. The capital raised will support the expansion of CT:VQ™ in Europe, including commercial integration and enhancing infrastructure to meet growing demand. The placement will increase shares on issue by approximately 2.45%.

Spacetalk Limited Raises AU$6.0 Million for Expansion
Spacetalk (ASX: SPA) has announced a AU$6.0 million placement, issuing 100.23 million shares at a price of AU$0.060 per share. This offering is intended to strengthen the company’s capital position, primarily to fund app development, inventory investment, and working capital for future growth opportunities. Spacetalk Limited was priced at AU$0.060, reflecting a ~20% decline, as the market assesses the potential impact of the capital raise on the company's share structure and near-term performance.

Outlook

• 4DMedical aims to leverage the CE Mark certification and the AU$83 million raise to expand CT:VQ™ across Europe, tapping into one of the largest respiratory imaging markets globally.
• Spacetalk is positioning itself for future growth in the tech and telecommunications sectors with its AU$6.0 million capital raise, focusing on enhancing app technology and securing inventory for expansion.

Both companies are taking steps to drive growth in their respective sectors, with 4DMedical enhancing its global footprint and Spacetalk expanding its technology and infrastructure to meet future demand.

Note - All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au